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Abstract. As the complexity of radiation therapy has increased, the need for quantitative 
dosimetric evaluation of treatment delivery has also increased.  A growing number of 
investigations have expanded the use of EPIDs from anatomic applications to dosimetric 
verification.  This work focuses on the applications of EPIDs for pre-treatment dosimetric 
verification of IMRT and intensity modulated arc therapy techniques.  The advantages and 
disadvantages of these techniques are discussed along with methods to extrapolate to 3D dose 
verification applications. 
1.  Introduction 
The evolution of radiation therapy treatment planning and delivery methods has required a similar 
evolution for the dosimetric methods for evaluation.  Delivery techniques such as intensity modulated 
radiation therapy (IMRT) and intensity modulated arc therapy (IMAT) require more detailed spatial 
information.  As the need for pre-treatment patient-specific quality assurance has increased, so have 
investigations into the use of electronic portal imager detectors (EPIDs).  EPIDs offer advantages 
compared to other systems in that they are attached to the gantry and are sold with the majority of new 
accelerator purchases.  They are also efficient to use and do not require the set up of any additional 
equipment once the system has been commissioned for such a purpose.  However, the response of 
EPIDs to radiation is complex due to their composition.  These systems were designed and optimized 
to require as little delivered dose as possible to obtain a high quality image that can be used for patient 
localization.   
EPIDs have been investigated for both pre-treatment and transit dosimetry applications.  These 
different types of portal dosimetry methods have been comprehensively reviewed by van Elmpt et 
al.[1]  Transit or in vivo dosimetry methods have been developed and reported on by investigators at 
the Netherlands Cancer Institute (see conference paper by Mijnheer et al).[1-5]  These methods 
typically utilize the commercial configuration of the device.  Additional software tools and acquisition 
methods have been developed with EPIDs to verify the accuracy of a delivered treatment pre-
treatment without a patient and with or without a phantom present. The majority of these pre-treatment 
investigations have been performed utilizing commercial EPID systems in an indirect detection 
configuration where the system includes a scintillation-layer as part of the manufacturer supplied 
configuration.  Other investigators have used direct detection configurations where no scintillation 
layer is present.  This work focuses on methods developed for amorphous silicon-based systems for 
pre-treatment quality assurance methods. 
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2.  EPID Dosimetry with Standard Configurations 
Amorphous silicon EPIDs have been investigated for dosimetric applications for IMRT and arc 
therapy techniques.  Reliable use of the system requires commissioning of the planning and delivery 
system prior to development of the EPID-based program.  Then, it may be appropriate to establish a 
pre-treatment QA program based on calculations in the EPID compared with the EPID response.  
These methods typically rely on determining the appropriate parameters of operation of the EPID and 
accurate determination of correction factors and the accuracy of the calculation of a predicted portal 
dose image (PDI).[6-12]  The features of the measurement are affected by the frequency of the data 
acquisition and communication speeds.  The response itself can be affected by ghosting and lag.  The 
response of these systems depends on the field size.  
The presence of the scintillator results in an increased sensitivity to low energies.  For example, the 
effect of the different layers of material and backscatter on the detector response as a function of 
energy has been quantified using Monte Carlo calculations.[13]  Therefore the response of the system 
is dependent on the energy spectrum of the delivered beam.  In some investigations, additional buildup 
is added to provide additional attenuation of the beam.  Initial investigations demonstrated a clear dose 
rate effect due to saturation of the detector.[8] 
2.1.  Calculating the Predicted Portal Dose Image (PDI) 
For pre-treatment QA, the EPID response is measured and then compared to the predicted portal dose 
image (PDI).  This method is used to verify the accuracy of the intended fluence.  The measured 
response is compared to a calculation in the imager rather than converting the imager response to dose 
in water.  Initial methods used pencil beam methods to predict the portal dose image.[8]  Other 
methods involved calculating separate fluences for the primary and scatter components.[6, 7]  More 
recently, investigators have used Monte Carlo to create EPID-specific dose kernels.  For example, one 
method uses Monte Carlo to incorporate details of the multileaf collimator design such as 
transmission, tongue-and-groove, and curved leaf ends.[9]  In another study, Monte Carlo was used to 
generate imager-specific dose kernels to investigate different thicknesses of backscattering.[14]  Other 
considerations included determination that the effect of backscatter due to the metallic components of 
the support arm can be as much as 6% for large fields.[15] 
With the corrections applied, the majority of these studies found agreement of >90% of the points 
to be within criteria 2%/2 mm for dose and distance, respectively for IMRT and IMAT deliveries.  
These studies demonstrate the complexity of modeling required for robust use of EPIDs for IMRT pre-
treatment QA. 
2.2.  Measuring the Portal Dose Image (PDI) 
When operated in an integrative mode during delivery, amorphous silicon EPIDs have been found to 
have a reproducible response which is essential for dosimetric applications.[7, 8]  Investigators have 
characterized the response for a range of field sizes, doses, dose rates, and source-to-detector 
distances.  Continuous acquisition mode has also been investigated for EPID verification for IMRT 
and IMAT delivery methods to allow for discrimination of time-based information.  In this mode, 
some information is lost during the readout and the system was determined to have a non-linear 
response to dose for low doses.[12]  The system was found to be reliable for the IMRT and arc therapy 
fields that were evaluated.  For arc and IMRT applications, there are discrepancies for deliveries of 
low monitor units.[8, 10, 12]  These need to be further evaluated to ensure that EPID techniques are 
only used in validated situations. 
3.   Dosimetry with Direct Detection Configurations 
Due to the difficulties in modeling scatter and the fact that the measured response differs substantially 
from dose in water, work has also been done using amorphous silicon-based systems in a direct 
detection configuration.[16-20]  Because these systems do not have a scintillator, the overall signal is 
much lower.  The measured signal is converted to dose more simply than with indirect detection 
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systems although there the dark field must be adequately measured.  The devices can be operated in 
continuous or integrated modes with considerations similar to commercial systems about loss of data 
in the continuous acquisition mode.[16, 18]  The configuration results in measured results that are 
much more similar to those in water, even with minimal backscatter.[20]   
4.   3D Applications 
In vivo dosimetry methods rely on the backprojection of the measured response to a plane in the 
patient or phantom.[1]  With cone beam CT data more readily acquired as part of a patient’s treament, 
3D verification of the actual delivered dose is becoming feasible. Methods for 3D dose verification 
have been developed for hypofractionated lung treatments[4, 21] and prostate, rectum, and head-and-
neck treatments[5].  Methods are being developed to account for artifacts in the cone beam CT 
images.[22, 23]  Monte Carlo methods have been used to reconstruct the dose in a phantom as a 
function of the measured exit dose for an IMRT treatment.[24]  These methods promise must more 
information about the accuracy of the delivered dose to patients.   
5.   Summary 
As radiation therapy continues to increase in complexity, it is crucial to have validated and easy to use 
methods to verify that the correct treatment plan was delivered to the patient.  Information that has 
previously been obtained solely for adaptive therapy purposes can be used to develop more 
sophisticated models of the patient over the course of treatment.  Methods to use commercial EPID 
systems for verification of IMRT and IMAT treatments have been developed and are in use in some 
centers.  When used in the standard configuration (indirect mode), a number of correction factors must 
be applied to the measurement and to properly calculate the predicted portal dose image.  Transit 
dosimetry methods have also been developed and the derived information is being coupled 
successfully with cone beam CT information to develop models of the 3D delivered doses.  The 
accuracy of these methods must be validated with dosimetry systems of known performance.  From a 
safety perspective, the use of EPID information to reconstruct 3D doses provides much more 
information about the quality of a patient delivery.  This area is expected to mature over the next few 
years.   
 
Table 1.  Summary of investigations into the use of EPIDs for pre-treatment verification in a standard 
configuration for advanced technology treatments.  
 
First Author/Year Method Conditions Limitations 
van Esch et al. 2004 Measurement: 
integrated acquisition 
mode; averaged gray 
scale image converted 
to portal dose image 
(PDI) 
Calculation: predicted 




 to 25 x25 cm
2
 
for SDD=105 cm; 
SMLC/DMLC 
Adversely affected by 
saturation of the 
detector at 600 
mu/min dose rate 
Chytyk et al. 2009 Improved calculation: 
Two-source fluence 
model with focal and 
extra-focal sources; 
more detailed modeling 
of jaws and MLC; 









Tested: Fields for 10 
prostate and 10 
oropharyngeal patient 
plans 
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McCurdy et al. 2009 Measurement: 
continuous acquisition 
mode 
IMRT and IMAT 
techniques 
Difficulties with 
verification of low 
MU; significant 








between EPID and 
collimator housing to 
keep EPID position 
stable during rotation 
Calculation: pencil 
beam kernels derived 
from measurements 
23 Treatment fields 
delivered with both 
IMRT and IMAT 
techniques 
Compared to an ion 
chamber 10% 
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